Galactorrhoea with moclobemide

Lancet

Volumn 351, Issue 9105, 1998, Pages 802-

  Dunn, N R ^a   Freemantle, S N ^b   Pearce, G L ^b   Mann, R D ^b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; FLUVOXAMINE; MOCLOBEMIDE; PAROXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CONFUSION; DATA ANALYSIS; DEPRESSION; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; SLEEP DISORDER; VERTIGO;

EID: 0032515838     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78928-5     Document Type: Article

References (4)

1. 1 Summary of Product Characteristics for Manerix (Moclobemide), Roche, June 1997.
2. 2 Freeman H. Moclobemide. Lancet 1993; 342: 1528-31.
3. 3 Freemantle SN, Pearce GL, Wilton LV, et al. The incidence of the most commonly reported events with 40 newly marketed drugs - a study by prescription-event monitoring. Pharmacoepidemiol Drug Safety 1997; 6 (suppl 1): 1-62.
4. 4 Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational studies. Pharmacoepidemiol Drug Safety 1997; 6: 235-47.